Chronic kidney disease (CKD) and type 2 diabetes (T2D) are associated with an increased risk of incident heart failure (HF). Finerenone, a non-steroidal mineralocorticoid antagonist (MRA) with favorable effects on cardiorenal outcomes, represents a new pillar in the treatment of CKD in T2D. It is currently being investigated in an extensive rial program for its potential benefits in people with HF.

In this session, recognized experts will discuss the unmet needs in CKD and HF management, the therapeutic benefits of MRAs in patients with CKD associated with T2D, and their potential future role in the treatment of HF.